During the duration of the CRADA, GA had more technical staff members involved in the design and development of accelerators and accelerator technology than any other firm in the United States. In addition to this CRADA in medical accelerator technology, GA has full responsibility for the accelerator for the Accelerator Production of Tritium program, the nation's largest current accelerator development program. Boron Neutron Capture Therapy (BNCT) and food irradiation are the two long-term applications of accelerators that receive major corporate support.
CRADA Mission:
Under this CRADA, Berkeley Lab and the industry partner, GA, have cooperatively developed hadron therapy technologies for commercialization. Specifically, Berkeley Lab and GA jointly developed beam transport systems to bring the extracted protons from the accelerator to the treatment rooms, rotating gantries to aim the treatment beams precisely into patients from any angle, and patient positioners to align the patient accurately relative to the treatment beams. We have also jointly developed a patient treatment delivery system that controls the radiation doses in the patient, and hardware to improve the accelerator performances, including a radiofrequency ion source and its low-energy beam transport (LEBT) system. This project facilitated the commercialization of the DOE-developed technologies in hadron therapy by the private sector in order to improve the quality of life of the nation.
CRADA Achievements:
The development of a proton therapy facility is a complex technological task as it involves developing diverse technical components to perform various functions, such as:
• proton acceleration
• beam transport from the accelerator to the patient irradiation rooms
• accurately and reliably directing the beam into the patients from any angle
• modification of the proton beam to make it suitable for treating cancer targets
• monitoring and control of the treatment delivery The CRADA goals have been met in many different ways. In this report we will divide the methodologies into the following four parts:
1. Collaborative R&D in designing technical components of the proton therapy facility
Under this CRADA, Berkeley Lab critically reviewed the GA's engineering designs of the proton beam-line optics, rotating gantries, and patient positioners. Interactions between Berkeley Lab and GA through frequent meetings and reviews have provided transfer of technology necessary to solve critical problems that are central to achieving technically superior and cost-effective proton therapy. The technical components addressed in the CRADA include:
• Beam Transfer System (BTS):
• Quadrupole and 30-degree dipole magnets
• BTS controls, diagnostics, and safety system
• Patient positioner System (PPS):
• Two PPS were designed, fabricated, installed at NPTC, and tested. The PPS has very good accuracy (<0.5 mm) and superb repeatability ( 70 µm • The rotating gantry was designed by GA.
• 135-degree dipole magnets were designed, fabricated, installed on a gantry and tested at NPTC.
• 45-degree dipole magnets were designed, fabricated, installed on a gantry, and tested at NPTC.
Furthermore, we have designed a radio frequency (rf) driven multicusp ion source for a 13.56 MHz operation with high proton percentage. The ion source has been designed, fabricated, and tested. An ion-optics computation was done and performance comparison was made among various electrode configurations of an electrostatic low-energy beam transport (LEBT) system. In our final design, the LEBT system consists of six electrodes, and can accelerate both 35 mA and 72 mA protons by adjusting electrode potentials without changing the mechanical parts. This newly-designed LEBT system conformed to the acceptance parameters of the Loma Linda type radio-frequency quadrupole (RFQ) with the proton beam accelerated to 35 keV. The ion-source-LEBT system developed under this CRADA is versatile and can be applied to different RFQ structures. We have jointly developed a complete engineering design report on the LEBT System. At GA's request, Berkeley Lab has made available a complete quadrupole magnet design package (used in a prior facility to construct the Advanced Light Source at Berkeley Lab), including drawings and specifications which, with slight modifications, have been integrated into the GA product line. Quadrupole magnet laminations from thin sheet stock were successfully punched using the die supplied by Berkeley Lab. Quadrupole magnets were fabricated by the industry using the design and hardware provided by Berkeley Lab. These tools greatly shortened the quadrupole magnet schedule and enhance the effectiveness of factory testing of the hardware produced. Using this proven hardware has provided a significant risk reduction to the product development by GA.
Training of the industrial partner personnel
Under this CRADA, Berkeley Lab provided GA with computational tools in proton beam optics design; Berkeley Lab trained several GA scientists to utilize the beam optics code to calculate the proton beam propagations and beam losses in channeling magnets. Berkeley Lab also trained the GA personnel in fabrication technique of magnets for the proton beam transport system. Berkeley Lab has provided GA the hardware designs and "know-how" to accurately position and align magnets and sensors in the beam line using proven hardware and alignment technique.
Industry/national laboratory collaboration in installation and testing of technical components of the proton therapy facility
Our industrial partner, GA fabricated proton beam transport systems and patient positioners. GA produced the engineering design of a rotating gantry. After this hardware, as well as the cyclotron and other technical components, were installed at NPTC in 1998, Berkeley Lab and GA jointly worked on the integration and testing of these components.
CRADA Benefit to DOE and LBNL:
Under the CRADA, we have transferred the DOE-developed medical accelerator technology to the private sector. The general public is the ultimate beneficiary as it will result in improved health care. "Accelerators for cancer cure" will clearly be understood by the public. Returning the fruits of Federally-funded research from the national laboratory to society exemplifies the rationale of supporting basic science research at national laboratories. This CRADA enhanced the public support of the Federally-funded research at national laboratories.
This CRADA enabled Berkeley Lab to retain scientific personnel in the field of medical applications of particle accelerators. 
CRADA Benefits to the Industrial Partner:
Through the CRADA, GA obtained the expertise residing in a national laboratory. This CRADA has enabled a US firm to deliver to a private hospital a most advanced proton facility based on the DOE-developed technologies, enhancing the competitiveness of the US firm in the international market.
On 22 Jun 2000, Thomas Hurn of GA <thomas.hurn@gat.com> wrote to W. T. Chu, P.I., "It was a pleasure working with you and your talented scientists and engineers at LBNL on this CRADA. They greatly improved our ability to meet the challenges of the program. I hope we have the chance to collaborate on projects like this in the future."
CRADA Benefits to the Public:
The potential payoffs of the CRADA are substantial in terms of improving the quality of life through reducing cancer mortality.
Commercialization of the Proton Therapy Technology:
The Status of the NPTC Proton Therapy Facility (6/2000):
All hardware components have been installed and integrated to form a complex proton therapy facility. (See: Y. Jongen, S. Laycock, et. al. (IBA) ; T. Hurn, L. Nissley, E. Hubbard, M. Heiberger, M. Tabor, G. Silke (GA), Toshiki Tachikawa, Masami Sano, et. al. (Sumitomo Heavy Industries) , "The Proton Therapy System for MGH's NPTC: Equipment Description and Progress Report," 1998.) The commissioning has been delayed to the year 2001 due to the problems with the development of the treatment delivery software, which is outside the scope of this CRADA.
Award and Recognition:
On May 10, 2000, the P. In the letter of commendation (May 10, 2000) to Dr. Chu, the Secretary of Energy Bill Richardson said, "Your accomplishment in the development of the Accelerator-Based Particle Therapy to Safely Destroy Cancerous Tumors and the promotion of its use in hospital-based medical accelerators has greatly enhanced the future development of proton therapy technologies. Your subsequent efforts in the cooperative agreement to establish the Northeast Proton Therapy Center at Massachusetts General Hospital in Boston will provide the environment for the production of the most technologically advance products in this field of proton therapy."
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